Ovarian Cancer Partnering Reviewed in New CurrentPartnering Study15 Mar 2012 • by Natalie Aster
Comprehensive study “Ovarian Cancer Partnering 2007-2012” by CurrentPartnering provides understanding and access to the ovarian cancer partnering deals and agreements entered into by the world leading healthcare companies.
The report provides an analysis of ovarian cancer partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors ovarian cancer technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Ovarian Cancer Partnering 2007-2012
Published: February, 2012
Price: US$ 995,00
This data driven report contains over 75 links to online copies of actual ovarian cancer deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
More information can be found in the report “Ovarian Cancer Partnering 2007-2012” by CurrentPartnering.
To order the report or ask for sample pages contact firstname.lastname@example.org